Lilly to present new clinical data for Verzenio and multiple novel pipeline programMEs at the 2025 ESMO annual meeting: Indianapolis Tuesday, October 14, 2025, 09:00 Hrs [IST] Eli ...

LONDON, GREATER LONDON, UNITED KINGDOM, October 14, 2025 /EINPresswire.com/ -- How Big Is The Targeted Alpha-Therapy Market In 2025? The market for targeted alpha-therapy has seen a significant surge ...

Background： Sepsis is a complex clinical syndrome characterized by dysregulated immune responses, systemic inflammation, and ...

Immatics is advancing Anzu-cel, a T-cell receptor therapy for melanoma with potential for significant annual revenue. Learn ...

Oral presentation by Dr Zan highlighted novel Phase 1/2 SANTANA-225 study design of 225Ac-SSO110 in patients with ES-SCLC or MCC225Ac-SSO110 ...

Psychological stress can impair the brain’s reward system, contributing to psychiatric disorders. A new study examines how a ...

FDA grants orphan drug designation to cintredekin besudotox, offering new hope for glioblastoma treatment with targeted ...

Sanofi reports that its AlphaMedix phase 2 trial showed strong efficacy and survival benefits in gastroenteropancreatic ...

AlphaMedixTM (212Pb-DOTAMTATE) achieved all primary efficacy endpoints in phase 2 study, demonstrating clinically meaningful benefits in ...

The FDA granted orphan drug designation to cintredekin besudotox for glioblastoma, supporting further research for this ...